Spots Global Cancer Trial Database for minimal residual disease
Every month we try and update this database with for minimal residual disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi | NCT05929222 | Follicular Lymp... | Radiotherapy Radiotherapy pl... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease | NCT06253650 | Gastric Cancer HER2-positive G... | Experimental Control | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| ctDNA Methylation Sequencing for Myeloma | NCT05578625 | Multiple Myelom... | plasma circulat... | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | NCT04716075 | Chronic Lymphoc... Chronic Graft-v... Mantle Cell Lym... Adverse Event Response Rate | Acalabrutinib 2... | 18 Years - 80 Years | Polish Lymphoma Research Group | |
| Circulating Tumor DNA Study in Patients With Endometrial Cancer | NCT05955079 | Endometrial Can... | Whole blood | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | NCT00560794 | Acute Lymphobla... | Blinatumomab (M... | 18 Years - | Amgen Research (Munich) GmbH | |
| Treatment of Adult ALL With an MRD-directed Programme. | NCT00358072 | Acute Lymphobla... | Postremission c... | 15 Years - 65 Years | Northern Italy Leukemia Group | |
| SCION: SABR and Checkpoint Inhibition Of NSCLC | NCT04944173 | Non Small Cell ... Carcinoma, Non-... Non-small Cell ... Lung Cancer Lung Cancer Sta... Lung Adenocarci... Lung Squamous C... | Durvalumab Stereotactic Bo... Circulating Tum... | 18 Years - | University of British Columbia | |
| Place of the Hevylite Test in the Evaluation of MRD in Myeloma | NCT03702088 | Myeloma | 18 Years - | University Hospital, Montpellier | ||
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | NCT05362942 | Relapsed Acute ... Refractory Acut... Minimal Residua... | Venetoclax, Dec... | 18 Years - | Beijing 302 Hospital | |
| Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors | NCT02400970 | Minimal Residua... Fertility Prese... | malignant cells | - | University Hospital, Clermont-Ferrand | |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive | NCT05603156 | Ph+ ALL Bone Marrow Tra... Minimal Residua... | the usage of Ol... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Prospective, Single-arm, Multicenter Clinical Study on Haploidentical Hematopoietic Stem Cell Transplantation in Patients With MRD Positive CD19+ALL Treated With Conditioning Regimens Containing Blinatumomab | NCT06125106 | Acute Lymphobla... | Blinatumomab | 18 Years - 70 Years | Zhejiang University | |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | NCT01751425 | Chronic Myeloge... Chronic Myeloge... Minimal Residua... Philadelphia Ch... | Dasatinib Imatinib Mesyla... Nilotinib Ruxolitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation | NCT05697913 | Multiple Myelom... | Continued treat... | 18 Years - 75 Years | Hospital Galdakao-Usansolo | |
| Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC | NCT05167604 | Carcinoma, Non-... Next-Generation... Chemotherapy, A... Neoplasm, Resid... Circulating Tum... | Adjuvants, Phar... | 18 Years - 70 Years | Tang-Du Hospital | |
| ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT | NCT04785547 | ALL, Childhood Minimal Residua... | Blinatumomab | 6 Months - 21 Years | St. Anna Kinderkrebsforschung | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia | NCT03367299 | Acute Lymphoid ... Philadelphia Ch... | Chemotherapy + ... | 18 Years - 65 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Chidamide With AZA in MRD Positive AML After Transplant | NCT06066905 | AML, Adult Minimal Residua... | chidamide and a... | 18 Years - | Guangdong Provincial People's Hospital | |
| Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants | NCT03624530 | Philadelphia Ch... Tyrosine Kinase... Minimal Residua... Allogeneic Hema... | Tyrosine kinase... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML | NCT03665480 | Granulocyte Col... Minimal Residua... Acute Myeloid L... | G-SCF | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pegasys in Patients With Chronic Myeloid Leukemia (CML) | NCT01392170 | Leukemia | PEG-IFNá-2a | 16 Years - | M.D. Anderson Cancer Center | |
| Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) | NCT05196087 | Breast Cancer Melanoma Gastrointestina... | 18 Years - | University Health Network, Toronto | ||
| Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia | NCT05093192 | Chronic Lymphoc... Minimal Residua... | Exercise trial | 18 Years - | University of Bath | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | NCT04179929 | Acute Lymphobla... | Pediatric-type ... allogeneic HSCT | 18 Years - 60 Years | PETHEMA Foundation | |
| Treatment of Adult ALL With an MRD-directed Programme. | NCT00358072 | Acute Lymphobla... | Postremission c... | 15 Years - 65 Years | Northern Italy Leukemia Group | |
| Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum | NCT02054104 | Thoracic Sarcom... Thorasic Cancer... Cancers of Non-... Sarcoma Melanoma | H1299 cell lysa... Cyclophosphamid... Celecoxib Iscomatrix adju... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | NCT04712942 | Acute Myeloid L... Myelodysplastic... Minimal Residua... | Pevonedistat Azacitidine | 18 Years - | University of Leipzig | |
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL | NCT04375683 | Acute Lymphocyt... BCR-ABL1 Fusion... | Flumatinib | 18 Years - 80 Years | Zhongda Hospital | |
| Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma | NCT05536700 | Multiple Myelom... | 18 Years - 85 Years | Institute of Hematology & Blood Diseases Hospital, China | ||
| MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT | NCT02673008 | Minimal Residua... Donor Lymphocyt... Hematopoietic S... Relapse | donor lymphocyt... | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease | NCT06253650 | Gastric Cancer HER2-positive G... | Experimental Control | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma | NCT05479708 | Pancreatic Canc... | ctDNA-based MRD... | 18 Years - 75 Years | Ruijin Hospital | |
| Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia | NCT04679285 | Acute Myeloid L... | 2 Years - 25 Years | University Hospital, Lille | ||
| Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD | NCT05137860 | Acute Lymphobla... Chemotherapeuti... Minimal Residua... | Bortezomib | 18 Years - 50 Years | Hospital General de Mexico | |
| Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery | NCT02314871 | Colon Cancer Minimal Residua... | Epidural analge... Piritramide Morphine | 18 Years - | The Institute of Molecular and Translational Medicine, Czech Republic | |
| Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | NCT03537599 | Minimal Residua... Recurrent Acute... Recurrent Adult... Recurrent Child... | Daratumumab Donor Lymphocyt... Laboratory Biom... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia | NCT01347996 | Acute Myeloid L... | histamine dihyd... | 18 Years - | Cytovia, Inc. | |
| Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies | NCT03241940 | B Acute Lymphob... CD19 Positive Minimal Residua... Philadelphia Ch... Recurrent Adult... Recurrent Child... Refractory Acut... | Chimeric Antige... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Questionnaire A... | 1 Year - 30 Years | Stanford University | |
| A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer | NCT05371873 | Hepatocellular ... | Liver resection... | 18 Years - 80 Years | First Affiliated Hospital of Zhejiang University | |
| Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology | NCT05969938 | Rectal Adenocar... Circulating Tum... Minimal Residua... Neoadjuvant Che... | MRD detection | 18 Years - 75 Years | Sun Yat-sen University | |
| Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) | NCT06358430 | Colorectal Canc... Minimal Residua... | Fludarabine Pho... Cyclophosphamid... Cetuximab TROP2-CAR-NK Ce... Rimiducid (AP19... Lymphodepleting... | 18 Years - | M.D. Anderson Cancer Center | |
| Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease | NCT00267085 | Chronic Myeloid... Minimal Residua... | Synthetic Tumor... | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia | NCT03697707 | Acute Myeloid L... | DCP-001 | 18 Years - | Mendus | |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | NCT00923013 | Hairy Cell Leuk... | Cladribine Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | NCT05182385 | ALL, Recurrent,... | Blinatumomab Venetoclax | 18 Years - | Goethe University | |
| Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation | NCT05697913 | Multiple Myelom... | Continued treat... | 18 Years - 75 Years | Hospital Galdakao-Usansolo | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | NCT05959720 | Acute Lymphoid ... Minimal Residua... Gene Abnormalit... Chemotherapeuti... | Prednisone Vincristin Daunorubicin Peg-asparaginas... Intrathecal Sus... Cyclophosphamid... Cytarabine Mercaptopurine Methotrexate Doxorubicin | 16 Years - 50 Years | Instituto do Cancer do Estado de São Paulo | |
| Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | NCT03699384 | Acute Myeloid L... Minimal Residua... | Azacitidine Avelumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Better Leukemia Diagnostics Through AI (BELUGA) | NCT04466059 | Hematologic Mal... Leukemia Minimal Residua... Lymphoma Blood Cancer | Automated AI-Gu... | 18 Years - | Munich Leukemia Laboratory | |
| CD19-CAR-T2 Cells for CD19 Positive Acute Lymphoblastic Leukemia | NCT04605666 | Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | CD19-CAR-T2 Cel... | 18 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma | NCT04122092 | Multiple Myelom... | The level of pl... | 18 Years - | Shanghai Changzheng Hospital | |
| Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC | NCT05167604 | Carcinoma, Non-... Next-Generation... Chemotherapy, A... Neoplasm, Resid... Circulating Tum... | Adjuvants, Phar... | 18 Years - 70 Years | Tang-Du Hospital | |
| Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors | NCT02400970 | Minimal Residua... Fertility Prese... | malignant cells | - | University Hospital, Clermont-Ferrand | |
| Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath | NCT00199030 | Adult Acute Lym... Lymphoma, Lymph... | Alemtuzumab (Ma... Cladribine | 18 Years - | Goethe University | |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | NCT03494569 | Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Hematopoietic C... Minimal Residua... Myelodysplastic... Secondary Acute... | Fludarabine Laboratory Biom... Melphalan Total Marrow Ir... | 12 Years - | City of Hope Medical Center | |
| The clonoSEQ® Watch Registry | NCT04545333 | Acute Lymphobla... Chronic Lymphoc... Multiple Myelom... Non-hodgkin Lym... | clonoSEQ Assay | 18 Years - | Adaptive Biotechnologies | |
| Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | NCT01158885 | Minimal Residua... Leukemia, Lymph... Leukemia, Myelo... | Clofarabine Cytarabine intr... Methotrexate Intrathecal (IT... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant | NCT04044560 | B-cell Adult Ac... Stem Cell Leuke... Minimal Residua... | blinatumomab | 1 Year - | University of British Columbia | |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | NCT03096782 | Accelerated Pha... Acute Biphenoty... Acute Leukemia Acute Lymphobla... Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chemotherapy-Re... Chronic Lymphoc... Chronic Myeloge... Chronic Myelomo... Hodgkin Lymphom... Langerhans Cell... Minimal Residua... Myelodysplastic... Myelodysplastic... Non-Hodgkin Lym... Recurrent Hodgk... Refractory Acut... Refractory Myel... Small Lymphocyt... Therapy-Related... | Anti-Thymocyte ... Busulfan Clofarabine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas | NCT05079022 | Adenocarcinoma ... | Furmonertinib | 18 Years - | Peking University People's Hospital | |
| Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | NCT04712942 | Acute Myeloid L... Myelodysplastic... Minimal Residua... | Pevonedistat Azacitidine | 18 Years - | University of Leipzig | |
| MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | NCT06198868 | Non-small Cell ... | Operable | 18 Years - | Jiangsu Cancer Institute & Hospital | |
| WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation | NCT01827137 | Multiple Myelom... Minimal Residua... High-Risk Cance... | WT1 Analog Pept... Sargramostim (G... lenalidomide | 18 Years - | Sellas Life Sciences Group | |
| Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab | NCT03982992 | B Cell Precurso... B-Cell Acute Ly... Acute Lymphobla... Acute Lymphobla... Acute Lymphobla... | Blinatumomab in... | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease | NCT03516279 | Chronic Phase C... Minimal Residua... | Dasatinib Imatinib Mesyla... Laboratory Biom... Nilotinib Pembrolizumab | 18 Years - | Eastern Cooperative Oncology Group | |
| Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL | NCT04375683 | Acute Lymphocyt... BCR-ABL1 Fusion... | Flumatinib | 18 Years - 80 Years | Zhongda Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
